Regional amyloid correlates of cognitive performance in ageing and mild cognitive impairment

Abstract Beta-amyloid deposition is one of the earliest pathological markers associated with Alzheimer's disease. Mild cognitive impairment in the setting of beta-amyloid deposition is considered to represent a preclinical manifestation of Alzheimer's disease. In vivo imaging studies are u...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain communications 2022, Vol.4 (1), p.fcac016
Hauptverfasser: Stevens, Daniel A., Workman, Clifford I., Kuwabara, Hiroto, Butters, Meryl A., Savonenko, Alena, Nassery, Najilla, Gould, Neda, Kraut, Michael, Joo, Jin Hui, Kilgore, Jessica, Kamath, Vidya, Holt, Daniel P., Dannals, Robert F., Nandi, Ayon, Onyike, Chiadi U., Smith, Gwenn S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Beta-amyloid deposition is one of the earliest pathological markers associated with Alzheimer's disease. Mild cognitive impairment in the setting of beta-amyloid deposition is considered to represent a preclinical manifestation of Alzheimer's disease. In vivo imaging studies are unique in their potential to advance our understanding of the role of beta-amyloid deposition in cognitive deficits in Alzheimer's disease and in mild cognitive impairment. Previous work has shown an association between global cortical measures of beta-amyloid deposition (‘amyloid positivity’) in mild cognitive impairment with greater cognitive deficits and greater risk of progression to Alzheimer's disease. The focus of the present study was to examine the relationship between the regional distribution of beta-amyloid deposition and specific cognitive deficits in people with mild cognitive impairment and cognitively normal elderly individuals. Forty-seven participants with multi-domain, amnestic mild cognitive impairment (43% female, aged 57–82 years) and 37 healthy, cognitively normal comparison subjects (42% female, aged 55–82 years) underwent clinical and neuropsychological assessments and high-resolution positron emission tomography with the radiotracer 11C-labelled Pittsburgh compound B to measure beta-amyloid deposition. Brain–behaviour partial least-squares analysis was conducted to identify spatial patterns of beta-amyloid deposition that correlated with the performance on neuropsychological assessments. Partial least-squares analysis identified a single significant (P 
ISSN:2632-1297
2632-1297
DOI:10.1093/braincomms/fcac016